Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

被引:76
作者
Bergman, AJ
Murphy, G
Burke, J
Zhao, JJ
Valesky, R
Liu, L
Lasseter, KC
He, WL
Prueksaritanont, T
Qiu, Y
Hartford, A
Vega, JM
Paolini, JE
机构
[1] Merck Res Labs, West Point, PA 19486 USA
[2] Merck Res Labs, Blue Bell, PA USA
[3] Merck Res Labs, Rahway, NJ USA
[4] Clin Pharmacol Associates, Miami, FL USA
关键词
Fenofibrote; simvastatin; pharmacokinetics; drug-drug interaction; HMG-CoA reductase; inhibitor;
D O I
10.1177/0091270004268044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Simvastatin and fenofibrate are both commonly used lipid-regulating agents with distinct mechanisms of action, and their coadministration may be on attractive treatment for some patients with dyslipidemia. A 2-period, randomized, open-label, crossover study was conducted in 12 subjects to determine if fenofibrate and simvastatin are subject to a clinically relevant pharmacokinetic interaction at steady state. In treatment A, subjects received an 80-mg simvastatin tablet in the morning for 7 days. In treatment B, subjects received a 160-mg micronized fenofibrate capsule in the morning for 7 days, followed by a 160-mg micronized fenofibrate capsule dosed together with an 80-mg simvastatin tablet on days 8 to 14. Because food increases the bioavailability of fenofibrate, each dose was administered with food to maximize the exposure of fenofibric acid. The steady-state pharmocokinetics (AUC(0-24h), C-max, and t(max)) of active and total HMG-CoA reductase inhibitors, simvastatin acid, and simvastatin were determined following simvastatin administration with and without fenofibrate. Also, fenofibric acid steady-state pharmacokinetics were evaluated with and without simvastatin. The geometric mean ratios (GMBs) for AUC(0-14h) (80 mg simvastatin [SV] + 160 mg fenofibrate)/(80 mg simvastatin alone) and 90% confidence intervals (CIs) were 0.88 (0.80, 0.95) and 0.92 (0,82, 1.03) for active and total HMG-CoA reductase inhibitors. The GMRs and 90% CIs for fenofibric acid (80 mg SV + 160 mg fenofibrate/160 mg fenofibrate alone) AUC(0-14h) and C-max were 0.95 (0.88, 1.04) and 0.89 (0.77, 1.02), respectively. Because both the active inhibitor and fenofibric acid AUC GMR 90% confidence intervals fell within the prespecified bounds of (0.70, 1.43), no clinically significant pharmocokinetic drug interaction between fenofibrate and siruvastatin was concluded in humans. The coadministration of simvastatin and fenofibrate in this study was well tolerated.
引用
收藏
页码:1054 / 1062
页数:9
相关论文
共 29 条
[21]   Effects of fibrates on metabolism of statins in human hepatocytes [J].
Prueksaritanont, T ;
Tang, CY ;
Qiu, Y ;
Mu, L ;
Subramanian, R ;
Lin, JH .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (11) :1280-1287
[22]   Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects [J].
Prueksaritanont, T ;
Vega, JM ;
Zhao, J ;
Gagliano, K ;
Kuznetsova, O ;
Musser, B ;
Amin, RD ;
Liu, L ;
Roadcap, BA ;
Dilzer, S ;
Lasseter, KC ;
Rogers, JD .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (05) :573-581
[23]   Cerivastatin and reports of fatal rhabdomyolysis. [J].
Staffa, JA ;
Chang, J ;
Green, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :539-540
[24]   Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography [J].
Streel, B ;
Hubert, P ;
Ceccato, A .
JOURNAL OF CHROMATOGRAPHY B, 2000, 742 (02) :391-400
[25]  
VICKERS S, 1990, DRUG METAB DISPOS, V18, P476
[26]  
WILMINGTON D, 2003, CRESTOR PRODUCT INFO
[27]   Effects of liquid chromatography mobile phase buffer contents on the ionization and fragmentation of analytes in liquid chromatographic/ionspray tandem mass spectrometric determination [J].
Zhao, JJ ;
Yang, AY ;
Rogers, JD .
JOURNAL OF MASS SPECTROMETRY, 2002, 37 (04) :421-433
[28]  
Zhao JJ, 2000, J MASS SPECTROM, V35, P1133, DOI 10.1002/1096-9888(200009)35:9<1133::AID-JMS42>3.0.CO
[29]  
2-X